<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4658">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811781</url>
  </required_header>
  <id_info>
    <org_study_id>Rovid</org_study_id>
    <nct_id>NCT04811781</nct_id>
  </id_info>
  <brief_title>Epidemiological Features and Clinical Course of SARS-CoV-2 Infection in Cancer Patients: The Rovid Study</brief_title>
  <official_title>Epidemiological Features and Clinical Course of SARS-CoV-2 Infection in Cancer Patients Within the Veneto Oncology Network: the ROVID Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to retrospectively collect epidemiological and clinical data in patients with&#xD;
      solid tumors and SARS Covid2 infections belonging to oncology centers within the Veneto&#xD;
      Oncology Network&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to create a Veneto Oncology Network with the aim of collecting&#xD;
      clinical and epidemiological data of cancer Patients affected by SAR- Covid-2 infection over&#xD;
      a period of 1 year. Descriptive statistical approaches will be used to process the data.&#xD;
&#xD;
      The aim is to evaluate the development rate of severe clinical forms of infection in patients&#xD;
      with SARS-Cov-2 and the possible association with tumour characteristics and treatment.&#xD;
&#xD;
      In addition, the results of serological tests can be compared with the outcome of the&#xD;
      diagnostic swabs and the clinical evolution of the infection in order to obtain more&#xD;
      information regarding the significance of specific antibody development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2020</start_date>
  <completion_date type="Anticipated">December 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of SAR-COV2 infection development in association with tumor characteristics.</measure>
    <time_frame>through study completion, an average of 18 months.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Cancer Patients with SARS-COV-2 infection.</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients with SAR COV-2 infection within the Veneto Oncology Network&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  be 18 Years and older&#xD;
&#xD;
          -  cancer patients belonging to Veneto 's Oncological Network&#xD;
&#xD;
          -  Patients with SAR COV-2 infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with no SAR COV2 Infection&#xD;
&#xD;
          -  Volunteers&#xD;
&#xD;
          -  No Cancer Patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierfranco Conte</last_name>
    <phone>0498215290</phone>
    <email>piefranco.conte@iov.veneto.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>istituto Oncologico Veneto -UOSD Melanoma</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanna Chiarion Sileni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aulss1 Dolomiti</name>
      <address>
        <city>Belluno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fable Zustovich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto -UOC Oncologia 1</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorina Zagonel</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

